000			02072 a2200589 4500
005			20250517150316.0
264		0	_c20180417
008			201804s 0 0 eng d
022			_a1029-2403
024	7		_a10.1080/10428194.2017.1307357 _2doi
040			_aNLM _beng _cNLM
100	1		_aLeblond, Véronique
245	0	0	_aA phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone. _h[electronic resource]
260			_bLeukemia & lymphoma _c11 2017
300			_a2615-2623 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aBayes Theorem
650	0	4	_aBortezomib _xadministration & dosage
650	0	4	_aDexamethasone _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aHematologic Diseases _xchemically induced
650	0	4	_aHumans
650	0	4	_aKaplan-Meier Estimate
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aProspective Studies
650	0	4	_aRemission Induction
650	0	4	_aWaldenstrom Macroglobulinemia _xdrug therapy
700	1		_aMorel, Pierre
700	1		_aDilhuidy, Marie-Sarah
700	1		_aLeleu, Xavier
700	1		_aSoussain, Carole
700	1		_aLeprête, Stéphane
700	1		_aDreyfus, Brigitte
700	1		_aDartigeas, Caroline
700	1		_aMahé, Béatrice
700	1		_aAnglaret, Bruno
700	1		_aPégourié, Brigitte
700	1		_aBesson, Caroline
700	1		_aAurran, Thérèse
700	1		_aVekhoff, Anne
700	1		_aTournilhac, Olivier
700	1		_aBanos, Anne
700	1		_aOya, Hervé
700	1		_aLejeune, Julie
700	1		_aOuzegdouh, Maya
700	1		_aChevret, Sylvie
773	0		_tLeukemia & lymphoma _gvol. 58 _gno. 11 _gp. 2615-2623
856	4	0	_uhttps://doi.org/10.1080/10428194.2017.1307357 _zAvailable from publisher's website
999			_c27067463 _d27067463